Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

M. N. Zamotaeva; V. I. Inchina; V. V. Konorev; Yu. V. Kuznetsov; N. D. Kuz’michev

doi:10.1007/s10517-018-4166-y

Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

Authors: Zamotaeva M.N.¹, Inchina V.I.¹, Konorev V.V.¹, Kuznetsov Y.V.², Kuz’michev N.D.¹
Affiliations:
1. N. P. Ogarev Mordovian National Research State University
2. N. M. Emanuel Institute of Biochemical Physics
Issue: Vol 165, No 3 (2018)
Pages: 344-346
Section: Article
URL: https://journals.rcsi.science/0007-4888/article/view/240286
DOI: https://doi.org/10.1007/s10517-018-4166-y
ID: 240286

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.